Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human AJUBA Antibodies:
anti-Mouse (Murine) AJUBA Antibodies:
anti-Rat (Rattus) AJUBA Antibodies:
Go to our pre-filtered search.
Human Polyclonal AJUBA Primary Antibody for IHC, IHC (p) - ABIN4278894
Tsuneki, Hardee, Michaud, Morotti, Lavik, Madri: A hydrogel-endothelial cell implant mimics infantile hemangioma: modulation by survivin and the Hippo pathway. in Laboratory investigation; a journal of technical methods and pathology 2015
Data show that AJUBA upregulated MMP10 (show MMP10 Antibodies) and MMP13 (show MMP13 Antibodies) expression in esophageal squamous cell carcinoma (ESCC).
Mechanistic investigations reveal that AJUBA specifically binds the FERM domain of JAK1 (show JAK1 Antibodies) to dissociate JAK1 (show JAK1 Antibodies) from the IFNgamma recepter, resulting in an inhibition of STAT1 (show STAT1 Antibodies) phosporylation and concomitantly its nuclear translocation. Clinically, the level of AJUBA in CRC (show CALR Antibodies) specimens is negatively correlated with the levels of IFIT2 (show IFIT2 Antibodies) and pSTAT1
AJUBA is a LIM domain protein and contributes to the formation and stability of cadherin-mediated cell-cell adhesion. Loss of AJUBA enhances Prostate cancer cell migration and downregulation of AJUBA expression is observed in metastatic Prostate cancer.
Mutations of the LIM protein (show CSRP1 Antibodies) AJUBA mediate sensitivity of head and neck squamous cell carcinomas to treatment with PLK1 (show PLK1 Antibodies) inhibitors.
mitotic phosphorylation of Ajuba is sufficient to promote cell proliferation and anchorage-independent growth in vitro and tumorigenesis in vivo
The results in this study uncovered that JUB was a regulator involved in proliferation of glioma cells, and it could be used as a potential therapeutic target for glioma.
AJUBA negatively regulates YAP activity through the LATS family, and inactivation of AJUBA is a novel key mechanism in malignant mesothelioma cell proliferation
the LIM protein JUB serves as a tumor-promoting gene in colorectal cancer by promoting epithelial-mesenchymal transition, a critical process of metastasis.
The LIM (show PDLIM5 Antibodies) domain of Ajuba can competitively bind to the N-terminal of Aurora-A (show AURKA Antibodies), and inhibited the interaction between N-terminal and C-terminal of Aurora A (show AURKA Antibodies).
A Rac-PAK1-Ajuba feedback loop integrates spatiotemporal signaling with actin remodeling at cell-cell contacts and stabilizes preassembled cadherin complexes.
Ajuba recruits p300/CBP (show CREBBP Antibodies) via its LIM (show PDLIM5 Antibodies) domain and facilitates p300/CBP (show CREBBP Antibodies) binding to PPARg (show PPARG Antibodies). Moreover, Ajuba, PPARg (show PPARG Antibodies), p300/CBP (show CREBBP Antibodies) can cooperatively occupy the PPARg (show PPARG Antibodies) target promoters and concomitantly increases histone acetylation at these loci.
Ajuba is a novel coactivator for liver X receptors and may play important role in lipid and glucose metabolism.
Findings support the importance of adhesion molecules (VE-cadherin and CD31), survivin, and Ajuba in modulating the Hippo pathway, which regulates, in part, proliferation and survival in hemangioendotheliomas.
PKD1-mediated phosphorylation of SNAI1 occurs in the nucleus and generates a nuclear, inactive DNA/SNAI1 complex that shows decreased interaction with its co-repressor Ajuba.
This paper presents evidence indicating that the human and mouse Ajuba is a new cytosolic component of the IL-1 (show IL1A Antibodies) signaling pathway, influencing the assembly and activity of the aPKC/p62 (show GTF2H1 Antibodies)/TRAF6 (show TRAF6 Antibodies) multiprotein signaling complex.
identification of the protein arginine methyltransferase 5 (PRMT5 (show PRMT5 Antibodies)) as an effector recruited to SNAIL (show SNAI1 Antibodies) through an interaction with AJUBA that functions to repress the SNAIL (show SNAI1 Antibodies) target gene, E-cadherin (show CDH1 Antibodies)
cytoplasmic LIM protein that binds glial glutamate transporter GLT-1 and is proposed to allow glial glutamate transporter GLT-1 to regulate intracellular signaling or interact with the cytoskeleton
LIM domain-containing protein ajuba
, jub, ajuba homolog
, protein ajuba
, Ajuba protein
, ajuba homolog